B r i e f c o m m u n i c at i o n s
The generation of neocortical neurons is restricted to development and these neurons are not renewed in adulthood in healthy humans 1, 2 . However, some studies in animal models and humans have suggested that cortical ischemic stroke induces neurogenesis [3] [4] [5] and neuronal DNA rearrangements 6 , which could contribute to the post-stroke recovery observed in surviving patients. We assessed, in post-mortem tissue from 20 stroke-affected individuals who died from nonneurological causes (Supplementary Table 1) , whether cerebral ischemia induces neurogenesis, causes DNA rearrangement or triggers DNA repair in human neocortex.
To characterize DNA content alterations in neurons after ischemic stroke, we isolated neuronal nuclei from human healthy (n = 5) and ischemic cortical tissue (n = 10) by flow cytometry (Fig. 1a and Supplementary Figs. 1 and 2) . DNA staining established that the vast majority of neuronal nuclei were diploid. However, there was a small population (<2%) of nuclei with a DNA content corresponding to a polyploid genome (Fig. 1b) . Fluorescent in situ hybridization (FISH) analysis of isolated neuronal nuclei with probes for the centrosome on chromosome 1, 7, 9 and 12 revealed, however, that all stroke tissue-derived neuronal nuclei (n = 100) from either the diploid or polyploid fraction showed only two FISH signals (Fig. 1c-e and data not shown). Thus, the neuronal nuclei of the polyploid fraction represent aggregates of diploid nuclei. Whole-genome sequencing did not detect any copy number variation in the neuronal population (n = 3; Supplementary Fig. 3 ). Although whole genome sequencing could not exclude the possibility of nonclonal copy number changes in single neurons, our data provide no evidence for aneuploidy or DNA content alterations of cortical neurons after ischemic stroke in humans.
To analyze whether ischemia induces genomic DNA fragmentation in neurons, which might be counteracted by endogenous DNA repair mechanisms 7 , we determined the degree of DNA breaks using the comet assay (Fig. 2a) . Fluorescence activated cell sorting (FACS)-isolated neuronal nuclei showed a significantly higher level (P = 0.012) of DNA fragmentation after acute/subacute ischemic cortical stroke as compared with healthy human cortex and chronic stroke lesions (Fig. 2b) . Moreover, a substantial proportion (19-22%) of neurons in the penumbra 7-20 d after stroke (n = 3) showed an upregulation of markers for DNA damage (double-strand breaks; Fig. 2c ) and repair (base excision; Fig. 2d ), which were not detected in healthy (n = 3) cortex tissue (transiently evident in mice 8 ) or in chronic (n = 3) stroke lesions ( Fig. 2e and Supplementary Fig. 4) . Notably, DNA repair marker-positive neuronal nuclei in three cases of subacute cortical ischemic stroke did not express markers of apoptosis, such as cleaved caspase-3 ( Supplementary Fig. 4 ). In humans, ischemiainduced neuronal DNA repair has not been reported in non-apoptotic neurons and might be a prerequisite for neuronal survival.
Genomic rearrangements that may occur after neuronal DNA repair in response to fragmentation-similar to chromothripsis as described recently in tumor tissue 9 -can be detected by the presence of fused gene transcripts. Transcriptome analysis by RNA-sequencing of cortical tissue of six ischemic stroke patients and cortex samples of six non-stroke control subjects (matched for age and gender) provided no evidence for substantial gene fusion events in ischemic cortical tissue as compared with healthy cortex (Supplementary Table 2 and Supplementary Fig. 5 ). According to our data, cortical neurons surviving ischemic stroke in humans did not exhibit substantial genomic rearrangements or translocations.
To assess the age of cortical cells after stroke, we determined the radiocarbon ( 14 C) concentration in their genomes. Retrospective 14 C dating has previously been established for birthdating of cells 1, 10 and to quantify the presence of neurogenesis 11 , or the lack thereof 2, 12 . The 14 C concentration in the DNA of neurons of healthy occipital control
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VOLUME 17 | NUMBER 6 | JUNE 2014 nature neuroscience B r i e f c o m m u n i c at i o n s cortex (n = 11) was not substantially different from atmospheric 14 C concentrations at the time of birth of the subjects (Fig. 3a and Supplementary Table 3) , indicating no postnatal neurogenesis, as described previously 1, 2 . The DNA of human cortical neurons surviving ischemic stroke (n = 11) was as old as the subject ( Fig. 3b and Supplementary Fig. 6 ). This establishes that ischemic cortical stroke does not elicit any detectable neurogenesis or extensive DNA synthesis between 3 d and 13 years after the ischemic event.
To address the possibility of stroke-induced generation of early neuronal progenitor cells in humans, we analyzed the expression of doublecortin (DCX), Tbr2 and Pax6 in acute ischemic lesions (n = 2). We did not detect any Pax6-or Tbr2-positive cells in the neocortex. However, we did detect several NeuN and DCX double-positive neurons as early as 7 d post stroke (Supplementary Fig. 7 ). Given that DCX/NeuN coexpression has not been observed earlier than 14 d after the onset of adult neurogenesis 13 , this finding indicates an upregulation of DCX in preexisting neurons (as described in the gyrus piriformis linked to plasticity effects 14 ) rather than early-stage neurogenesis after cortical stroke.
Consistent with a lack of any sustainable neurogenesis, we could not find any neuron in the adult human cortex, even after stroke, devoid of the age pigment lipofuscin (Supplementary Fig. 8 ), which post-mitotic cells accumulate with age 15 . However, in the penumbra adjacent to the stroke lesion core, the proportion of neurons with the most abundant lipofuscin deposits was lower than that in control tissue from the contralateral hemisphere, raising the possibility that high lipofuscin levels may represent a predisposing factor for ischemic neuronal death. As lipofuscin is absent in neurons of 5 years or younger in pediatric cortices 15 , we calculated that, in the individuals who had strokes at the earliest ages (2.6-5.6 years, n = 4), the maximum amount of undetected ischemia-induced neurogenesis must be less than 0.1% (1 in 1,000 neurons).
In contrast with the neuronal population, radiocarbon analyses revealed that the 14 C concentration in DNA from the non-neuronal cell population in the stroke lesions, that is, glia cells, vascular cells and other cell types involved in post-ischemic lesion consolidation, was on average higher than in controls (n = 11, P = 0.022; Fig. 3c ), indicating, as expected, an increased cellular turnover after ischemic stroke. Regression analyses indicated that the addition of new (nonneuronal) cells might not only be restricted to the time of stroke, but continue in the years after stroke.
By combining two independent approaches, 14 C and lipofuscin analyses, we found that, contrary to some experimental studies in animal models 16, 17 , there is no stroke-induced cortical neurogenesis or, if there is, the population of surviving new-born neurons is very small and unlikely to be clinically relevant. We revisited whether any cortical neurogenesis occurs after stroke in mice (n = 10). We found newly generated neuroblasts, co-expressing DCX and BrdU, in the peri-infarct cortex at 2 weeks after the injury (Supplementary Fig. 9 ). However, consistent with our human data, we were unable to detect Fig. 9 ).
Although we found evidence for DNA fragmentation and repair in neurons in the penumbra of the stroke, their genomic DNA had a 14 C concentration corresponding to the time of birth of the individual. Together with analyses of ploidy and genomic integrity, this suggests that there is little plasticity both in terms of neurogenesis or genomic rearrangements in human cortical neurons. Thus, the neurons that remain close to a stroke were generated during development and only neurons without extensive DNA damage survived long-term.
MethoDs
Methods and any associated references are available in the online version of the paper.
Accession codes. RNA sequencing data have been deposited at the GEO platform. The accession number is GSE56267. DNA sequencing data are available via the Sequence Read Archive (SRA) database (accession code SRP040676). FAcS sorting and analysis. Isolated nuclei were stained with mouse antibody to NeuN (A-60, Millipore, 1:1,000), rabbit antibody to Fox3 (Atlas Antibody, 1:300) or mouse antibody to HuD (E-1, Santa Cruz, 1:100). NeuN (A-60) antibody was directly conjugated to Alexa 647 (Invitrogen Antibody Labeling Kit Alexa 647). All other primary antibodies were visualized with appropriate secondary antibodies conjugated to Alexa 488 (1:500), Alexa 647 (1:500) (Invitrogen) or R-phycoerythrin (PE) (Santa Cruz, 1:100). Flow cytometry sorting was performed with a BD FACSDiva and flow cytometry analysis was performed with a BD FACSAria instrument. DNA content was determined using DRAQ5 (1:500) (Biostatus). FACS gating strategy for sorts is shown in Figure 1 and Supplementary Figures 1 and 2 . Correction for FACS impurities was done as described previously 12 . In case the sorting purity was less than 100%, FACS impurities were corrected using equations described previously 11 . Corrected values are shown in Supplementary Table 3. dnA purification. DNA isolation was performed as described before 11 . All experiments were carried out in a clean room (ISO8) to prevent any carbon contamination of the samples. All glassware was prebaked at 450 °C for 4 h. The collected nuclei were incubated at 65 °C over night in 500 µl of DNA lysis buffer (100 mM Tris (pH 8.0), 200 mM NaCl, 1% SDS (wt/vol), 5 mM EDTA) and 6 µl Proteinase K (20 mg ml −1 ). RNAse cocktail was added (Ambion) and incubated at 65 °C for 1 h. Half of the existing volume of 5 M NaCl solution was added and agitated for 15 s. The solution was spun down at 13,000 rpm for 3 min. The supernatant containing the DNA was transferred to a 5-ml glass vial. Three times the volume of absolute ethanol was added and the glass vial was inverted several times to precipitate the DNA. The DNA precipitate was washed three times in DNA washing solution (70% ethanol (vol/vol) and 0.1 M NaCl) and transferred to 500 µl of DNase/RNAase-free water (Gibco). DNA purity and quantity was determined by UV spectroscopy (NanoDrop).
Accelerator mass spectrometry. All AMS analyses were performed blind to age and origin of the sample and according to a protocol described previously 11 . Purified DNA samples suspended in water were lyophilized to dryness. To convert the DNA sample into graphite, excess CuO was added to each dry sample and the tubes were evacuated and sealed with a high temperature torch. Tubes were placed in a furnace set at 900 °C for 3.5 h to combust all carbon to CO 2 . The evolved CO 2 was cryogenically purified, trapped and reduced to graphite in the presence of iron catalyst in individual reactors at 550 °C for 6 h. Graphite targets were measured at Department of Physics and Astronomy, Ion Physics, Uppsala University 13, 18 . Large CO 2 samples (>100 µg) were split and δ 13 C was measured by stable isotope ratio mass spectrometry, which established the δ 13 C correction to −22.3 ± 0.5‰ (1 s.d.), which was applied for all samples. Corrections for background contamination introduced during sample preparation were made as described 13, 19, 20 . The measurement error was determined for each sample and ranged between ±4 and 12‰ (1 s.d.) ∆ 14 C for the large sample and small samples (10 µg C), respectively. All 14 C data are reported as decay-corrected ∆ 14 C or Fraction Modern.
Immunohistochemistry, FISH analysis and lipofuscin quantification. Fresh frozen brain tissue was sectioned at 20 µm with a Cryostat (ThermoFisher NX70) and post-fixed in phosphate-buffered saline (PBS)-buffered 2% formaldehyde (wt/vol) for 20 min according to standard procedures. Sections were incubated with the respective primary antibody overnight at 4 °C: mouse antibody to NeuN (Millipore A-60 clone, 1:100), rabbit antibody to Fox3 (Atlas Antibody, Hpa030790, 1:300), chicken antibody to MAP-2 (Abcam, ab5392, 1:1,000), mouse antibody to HuD (E-1, Santa Cruz, 1:100), rabbit antibody to caspase3 (Cell Signaling, Asp175, D3E9, 1:400), mouse antibody to gamma H2AX (3F2, Abcam, 1:200), mouse antibody to APE1 (Abcam, clone 13B8E5C2, 1:500) and guinea pig antibody to doublecortin (DCX; Millipore, AB5910, 1:1,000) and visualized with the matching secondary antibody conjugated to Alexa 488, 546 or 647 (1:1,000, Invitrogen). Tunel staining was performed according to instructions of the manufacturer (Roche). FISH analysis of isolated cortical nuclei was performed with fluorescent probes against the chromosome 7 centromere region (CEN-7) (EGFR/CEN-7 FISH Probe Mix, DAKO), chromosome 1 centromere region (Kreatech SE1 (1qh), chromosome 12 centromere region (Kreatech SE12 (D12Z3) and Cytology FISH Accessory Kit (DAKO) according to the instructions of the manufacturer. Based on z-stack confocal microscopy and auto-fluorescence in the Cy3 channel, the presence of lipofuscin in NeuNpositive cells was determined and the amount quantified as low (less than one third of the volume of the nucleus), medium (between one-and-two thirds) or high (more than two-thirds) 15 .
expression analysis of neun sorted nuclei. Nuclei isolates were labeled with mouse NeuN (Millipore A-60 clone; 1:1000), and flow cytometric sorted according to their immunoreactivity. Total RNA was extracted from NeuN positive and negative fractions (5-10 million nuclei), respectively, using the RNeasy mini plus kit (Qiagen). Equal amounts of total RNA from each sample were reverse transcribed to cDNA using the QuantiTect RT kit (Qiagen). In a final volume of 20 µL, 2 ng of cDNA was amplified using the following Taqman® assays (Applied Biosystems): FOX3, MAP2, IBA4, GFAP, CNP, SOX10, VWF and 18S ribosomal RNA. Quantitative real-time PCR was performed with a PRISM 7500 (Applied Biosystems). The relative mRNA levels were calculated using the comparative Ct method, using 18S rRNA as a normalizer. NeuN-positive nuclei served as a reference for FOX3 and MAP2. NeuN-negative sorted nuclei served as a reference for IBA4, GFAP, CNP, SOX10 and VWF.
dnA fragmentation analysis. A comet assay was performed according to ref. 21 , with slight modifications. Slides were coated with agarose (1.5% agarose in PBS) and dried horizontally 21 . 10,000 cells per 10 µl of PBS were mixed with 110 µl LMP agarose and poured on the precoated slides, covered with cover slip and left at 4 °C for 3 min. Cover slips were removed and cells were lysed for 2 h, at 4 °C in cold freshly made lysing solution (2.5 M NaCl, 100 mM EDTA and 10 mM Tris-HCl (pH 10), 1% Triton X-100 (wt/vol) and 10% dimethyl sulfoxide). After lysis, slides were incubated in ice-cold alkaline buffer (300 mM NaOH and 1 mM EDTA) for 20 min to allow unwinding of DNA. Electrophoresis was run in the same alkaline buffer at 25 V, 300 mA for 40 min. Slides were neutralized by drop-wise addition of neutralization buffer (0.4 M Tris-HCl, pH 7.5), 3 × 10 min and then fixed in absolute ethanol for 10 min. Intact or fragmented DNA was then visualized by ethidium bromide staining.
RnA sequencing and gene fusion analysis. Total RNA from one individual (one lesion site divided into two samples and one control sample, batch 1 in Supplementary Table 2 ) as well as total RNA from ten individuals (5 stroke patients and 5 control patients matched for sex and age, batch 2 in Supplementary Table 2) was extracted using RNeasy Mini extraction kit (Qiagen) according to the manufacturer's instructions. The extracted RNA was used to generate paired-end npg sequencing libraries using TruSeq RNA kits (Illumina) according to the manufacturer's instructions with the following changes; the protocols were automated using an Agilent NGS workstation (Agilent) and/or an MBS 1200 pipetting station (Nordiag AB), and all purification steps and gel-cuts were replaced by the magnetic bead clean-up methods as previously described 22 . The three samples were sequenced on an Illumina HiSeq2000. All sequences were mapped to the human reference genome (hg19) using TopHat (version 1.3.3) 23 . Putative PCR duplicates were removed from the aligned sequences using the MarkDuplicates subcommand of PicardTools (version 1.29, http://picard.sourceforge.net). Read counts were generated using HTSeq (version 0.5.1) (http://www.huber.embl.de/ users/anders/HTSeq/doc/overview.html) and fragments per kilobase of exon model per million fragments mapped (FPKM) values were calculated using Cufflinks (version 1.3.0) (http://cufflinks.cbcb.umd.edu). FusionMap (version 6.0 with default parameter settings) was used to search for putative expressed fusion genes separately in each sample by aligning fusion reads directly to the genome without prior knowledge of potential fusion regions 24 .
whole genome sequencing. Genomic 75-bp single-end DNA sequencing data (Illumina) were generated from healthy and lesioned tissue DNA (500 ng) to test for copy number changes. Illumina single-end sequencing resulted in on average 23 Mio uniquely mappable reads per sample, which were used to access CNVs in a sliding 100-kb window. After mapping with BWA 25 , the CNV-seq software 26 was used for counting reads in a sliding window of 100 kb. After chromosome-wise normalization, log 2 coverage ratios and their respective P values between healthy and lesioned tissue samples were calculated. Thresholds for CNV detection were p′ = 10 −3 and log 2 (r′) = 0.6.
Animals and experimental design. All experimental procedures had been approved by Malmö-Lund Ethical Committee. Ten young adult C57BL6 mice (no statistical methods were used to predetermine sample size, but sample size is similar to those generally employed in the field) were subjected to focal ischemic injury in cerebral cortex using distal middle cerebral artery occlusion (dMCAO). Focal ischemic injury was induced in cerebral cortex by permanent occlusion of the distal, pial branch of middle cerebral artery. Briefly, the temporal bone was exposed and a craniotomy of about 3-5 mm in diameter was made using the dental drill, 1 mm rostral to the junction of the zygoma and the squamosal bone. The dura mater was carefully opened, and the distal cortical branch of middle cerebral artery was isolated and cut after the electrocoagulation by bipolar forceps. The integrity of the temporal muscle was restored to close the cranial window, and the overlying skin was sutured. Immediately after stroke onset and then twice daily for 14 d thereafter, the mice were injected with BrdU (50 µg per kg of body weight, intraperitoneal). Animals were divided into two groups. The first group (n = 7) was perfused transcardially with saline followed by 4% paraformaldehyde (wt/vol) at 2 weeks and the second group (n = 3) at 4 weeks after stroke onset. Brains were removed and sectioned for immunohistochemical analysis. Experiments were not randomized and the assessment of DCX expression was not blinded to treatment status.
Analysis of neuronal and non-neuronal turnover in ischemic stroke patients.
In each patient, neuronal and non-neuronal samples from the ischemic lesion and the occipital cortex were measured. The cortex samples served as intraindividual controls. 14 C values were normally distributed as assessed by the Lilliefors test. The cortical control samples showed 14 C concentration corresponding to no postnatal turnover, consistent with our earlier study 2 , and therefore provided a good 14 C reference for detecting turnover in stroke samples. The mean 14 C concentrations of neurons in the ischemic lesion and cortex samples were −16.0 ∆ 14 C and −12.7 ∆ 14 C, respectively. A paired t test on the mean difference in 14 C showed that neurons in the ischemic lesions did not have significantly different 14 C values when compared with cortex controls (P = 0.452), indicating that neurons are not replaced in response to ischemic stroke. The non-neuronal population in the control cortex and in the ischemic lesion had significantly different genomic 14 C levels (t test, P = 0.022), indicating that the ischemic lesion triggered the generation of non-neurons. We concluded that non-neuronal cells respond to ischemic stroke by the addition of new cells. Regarding the question of whether the addition of new cells was associated with the time of stroke, we assumed that the new cells were created soon after stroke, or at least in the same year. Hence, we looked at the correlation of 14 C levels and time of stroke using a linear regression model: C S − C C = p1 × t + p2 (where C S = 14 C in stroke sample, C C = 14 C in cortex control, (C s − C c ) = 14 C of stroke sample in relation to its control, t = time of stroke). The coefficient of determination (R 2 = 0.135) indicated no correlation, suggesting that the addition of new cells might not only be restricted to the time of stroke, but continue in the years after stroke.
